Immunophenotyping and Mutation Analysis of Canine Intestinal T-Cell Lymphoma: A Comparative Pathological Study of Human Enteropathy-Associated T-Cell Lymphoma

犬肠道T细胞淋巴瘤的免疫表型和突变分析:与人类肠病相关T细胞淋巴瘤的比较病理学研究

阅读:3

Abstract

Human enteropathy-associated T-cell lymphoma (EATL) is a rare primary aggressive intestinal T-cell lymphoma associated with celiac disease and is considered to be a neoplasm of intraepithelial lymphocytes (IELs) with an innate lymphoid cell (ILC)-like immunophenotype. The lack of an animal model has delayed the elucidation of its pathogenesis. In dogs, the histopathological and immunophenotypic features of intestinal large T-cell lymphoma (ILTCL) are similar to EATL; however, its cell of origin remains unclear. We herein performed detailed immunophenotyping, an RNA expression analysis of selected genes, and gene mutation analysis of 54 cases of ILTCL, including 27 with fresh frozen samples available and 21 of intestinal small T-cell lymphoma (ISTCL) in dogs. Canine ILTCL was characterised by the expression of cytotoxic granules (53/54) and frequent absence of CD4/CD8 (26/27) and T-cell receptors (14/27). The mRNA expression of CD103 (25/35) and NKp46 (15/35) was detected in ILTCL by RNA in situ hybridisation. The gene mutation analysis showed mutations in NFKBIA (ILTCL, 31/54; ISTCL, 10/21), including truncating mutations (ILTCL, 11/54; ISTCL, 3/21). Mutations in STAT3 SH2 were less frequent (ILTCL, 13/54; ISTCL, 3/21) and the hotspot JAK1 mutation of human EATL was not detected. Immunohistochemistry for p-Stat3 showed STAT3 pathway activation in ILTCL cases. These results suggest that canine ILTCL is also a neoplasm of IEL with an ILC-like immunophenotype and STAT3 pathway activation, and loss-of-function mutations in NF-κB pathway inhibitors are associated with its neoplastic changes. Therefore, canine ILTCL has potential as a valuable model for investigating the pathogenesis of EATL.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。